Date: 2015-06-17
Type of
information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the 13th International Conference on Malignant Lymphoma taking place in Lugano
Company: Immunogen (USA - MA)
Product: IMGN529 and rituximab
Action
mechanism:
- antibody drug conjugate/monoclonal antibody. IMGN529 is a CD37-targeting antibody drug conjugate (ADC) created by ImmunoGen for the treatment of B-cell malignancies. It consists of a CD37-binding antibody with one of the Company's potent cancer cell-killing agents, DM1, attached. The antibody serves to deliver the DM1 specifically to B cells to kill them and, based on preclinical research, also contributes anticancer activity.
- Rituximab is a therapeutic monoclonal antibody that binds to the CD20 antigen on the surface of normal and malignant B-cells. It then recruits the body’s natural defenses to attack and kill the marked B-cells. Stem cells (B-cell progenitors) in bone marrow lack the CD20 antigen, allowing healthy B-cells to regenerate after treatment and return to normal levels within several months.
Disease: non-Hodgkin lymphoma
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On June 17, 2015, ImmunoGen, a biotechnology company that develops targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology, announced the first presentation of findings with the Company’s CD37-targeting ADC, IMGN529, in combination with the CD20-targeting antibody, rituximab (Rituxan®), in preclinical assessments. These data are being presented in a poster at the 13th International Conference on Malignant Lymphoma taking place in Lugano, Switzerland (abstract #P-274).
- Among the findings being presented are: IMGN529 exhibits strong synergy with rituximab and other CD20-targeting antibodies in cell lines representative of an array of non-Hodgkin lymphoma (NHL) subtypes, including both GCB and ABC diffuse large B-cell lymphoma (DLBCL); Consistent with the in vitro findings, the combination of IMGN529 and rituximab was highly active against DLBCL models in vivo; Synergy also was seen in vitro in a model representative of “double hit” lymphoma, a particularly difficult-to-treat type of DLBCL characterized by deregulation of two different genes, BCL2 (or BCL6) and MYC; and Both IMGN529’s antibody component and its DM1 payload contributed to its synergistic activity with rituximab.
- IMGN529 is currently in Phase I clinical testing for the treatment of NHL, used as a single agent in patients with heavily pre-treated disease. It has demonstrated encouraging evidence of activity, particularly for patients with relapsed/refractory DLBCL.1 Later this year, ImmunoGen plans to begin assessing IMGN529 used in combination with rituximab for the treatment of relapsed/refractory DLBCL in addition to assessing it as a single agent in DLBCL and chronic lymphocytic leukemia disease-specific patient populations.
Is
general: Yes
